Beta-Carotene and Vitamin C: study protocols
25 study groups took Beta-Carotene together with Vitamin C. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Beta-Carotene
25 study groups in 14 studies say how much Beta-Carotene participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 48% of 25 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mg or less | 1 |
| 1 mg to 2.5 mg | 2 |
| 2.5 mg to 5 mg | 0 |
| 5 mg to 10 mg | 9 |
| 10 mg to 25 mg | 12 |
| over 25 mg | 1 |
Dose per serving from research: Vitamin C
25 study groups in 14 studies say how much Vitamin C participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 64% of 25 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 9 |
| 250 mg to 500 mg | 16 |
Commonly used together
25 of 25 study groups took Beta-Carotene and Vitamin C with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin E | 22 |
| Zinc | 14 |
| Selenium | 10 |
25 study groups
| Study | ||||
|---|---|---|---|---|
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 15 mg | 500 mg | 8 years | — |
| Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13 2004 · antioxidants alone · Adults aged 55–81 years with age-related macular degeneration categories 1–4 or other AREDS ocular eligibility; participants in AMD categories 2–4 were eligible for this arm, and category 1 participants could also receive antioxidants | 15 mg | 500 mg | 339 weeks | — |
| Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 2013 · Antioxidants · Adults aged 55–80 with age-related macular degeneration (AREDS categories 1–4) | 15 mg | 500 mg | 339 weeks | — |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 15 mg | 500 mg | 8 years | — |
| Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13 2004 · antioxidants plus zinc · Adults aged 55–81 years with AMD categories 2–4 and AREDS ocular eligibility | 15 mg | 500 mg | 339 weeks | — |
| The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals 2004 · antioxidant supplement group · French women aged 35–60 and men aged 45–60 in the general population | 6 mg | 120 mg | 2739 days | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin plus vitamin A · HIV-positive pregnant Tanzanian women | 30 mg | 500 mg | — | — |
| Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels? 2005 · daily antioxidant supplementation · French adults: women aged 35–60 years and men aged 45–60 years | 6 mg | 120 mg | 2739 days | — |
| Antioxidant supplementation increases the risk of skin cancers in women but not in men 2007 · antioxidant group · French adult women and men in a general-population primary-prevention trial | 6 mg | 120 mg | 2738 days | — |
| Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 2013 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration (AREDS categories 1–4) | 15 mg | 500 mg | 339 weeks | — |